OakChart

Tactile Systems Technology Inc

TCMDHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 1:42 PM ET

26.79+0.17 (0.65%)
2026-11-11 19:42 CET
Market cap
596.33 USD m
Revenue, TTM
356.42 USD m
Net income, TTM
23.82 USD m
Free cash flow, TTM
29.02 USD m
EPS diluted, TTM
1.03
P/E
25.97
Compare

Price

TCMD against its 20, 50 and 200-day averages
2050200beat
25.0030.00719K1.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TCMDclose 26.7920-day 24.3950-day 23.16200-day 25.7126.7952w low

29.1% under the 52-week high of 37.77 on 18 Feb 2026. 52-week low 20.53 on 5 May 2026. Last 15 sessions, 36.7% high to low

Profile

TCMD
52-week range, 36% of the way up
20.5337.77

Tactile Systems Technology, Inc. engages in developing and providing medical devices for the treatment of underserved chronic diseases. It provides lymphedema solutions and offers Flexitouch Plus and Entre Plus systems products. The company was founded on January 30, 1995 and is headquartered in Minneapolis, MN.

IndexRUT
Employees1086
IPOJul 28, 2016
Beta0.86
ATR, 14d1.12
Rel volume0.36
Short float12.88%
Insider own3.34%
Inst own103.33%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap600.18M
Enterprise Value542.14M
Income23.82M
Sales356.42M
Book/sh10.10
Cash/sh3.35
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees1086
IPOJul 28, 2016

Ratios

P/E25.97
Forward P/E17.90
PEG0.53
P/S1.68
P/B2.65
P/C7.99
P/FCF20.68
EV/EBITDA13.37
EV/Sales1.52
Quick Ratio3.18
Current Ratio3.51
Debt/Eq0.08
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)1.03
EPS next Y1.50
EPS next Q0.55
EPS this Y37.80%
EPS next Y32.45%
EPS next 5Y33.82%
EPS past 3/5Y- -
Sales past 3/5Y10.12% 11.98%
EPS Y/Y TTM34.35%
Sales Y/Y TTM14.41%
EPS Q/Q-14.78%
Sales Q/Q7.12%
EarningsNov 02 AMC
EPS/Sales Surpr.12.03% -0.15%

Ownership

Insider Own3.34%
Insider Trans-3.28%
Inst Own103.33%
Inst Trans-4.03%
ROA8.65%
ROE11.02%
ROIC9.88%
Gross Margin76.31%
Oper. Margin9.46%
Profit Margin6.68%
SMA209.84%
SMA5015.66%
SMA2004.21%
Trades-

Technical

Shs Outstand22.50M
Shs Float21.65M
Short Float12.88%
Short Ratio9.39
Short Interest2.79M
52W High37.77 -29.06%
52W Low20.53 30.50%
Volatility5.58% 4.50%
ATR (14)1.12
RSI (14)66.62
Beta0.86
Rel Volume0.36
Avg Volume296.93K
Volume71,417

Performance

Perf Week-1.43%
Perf Month20.09%
Perf Quarter13.00%
Perf Half Y15.04%
Perf YTD-7.61%
Perf Year6.74%
Perf 3Y150.16%
Perf 5Y-9.97%
Perf 10Y44.90%
Recom1.00
Target Price36.33
Prev Close26.62
Price26.79
Change %0.65%

Analyst ratings

latest 10 of 19
DateActionAnalystRating changeTargetImplied
May 07, 2026UpgradeRB. Riley SecuritiesNeutral → Buy$36+34.4%
Jan 05, 2026UpgradePPiper SandlerNeutral → Overweight$35+30.6%
Nov 04, 2025UpgradeBBTIG ResearchNeutral → Buy$28+4.5%
Oct 03, 2025InitiatedLLake StreetBuy$23.50-12.3%
May 06, 2025DowngradePPiper SandlerOverweight → Neutral$14-47.7%
Feb 19, 2025DowngradeRB. Riley SecuritiesBuy → Neutral$23 → $18-32.8%
Nov 05, 2024DowngradeOOppenheimerOutperform → Perform
Nov 05, 2024DowngradeBBTIG ResearchBuy → Neutral
Sep 26, 2024InitiatedRB. Riley SecuritiesBuy$23-14.2%
Nov 13, 2020UpgradeOOppenheimerPerform → Outperform$55+105.3%

Peers

Mkt cap
TickerCompanyMkt cap
ELMDElectromed Inc205.31M
INGNInogen Inc148.86M
VMDViemed Healthcare Inc344.83M
AHCOAdaptHealth Corp1.06B
ENOVEnovis Corp1.66B
INFUInfuSystem Holdings Inc307.21M
KIDSOrthoPediatrics corp881.36M
SMTISanara MedTech Inc290.98M
RMDResmed Inc33.09B
MMSIMerit Medical Systems Inc5.26B

Insider trading

latest 14 of 23
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BURKE WILLIAM WDirectorNov 04 '26Sale27.005,000135,00050,041Nov 09 06:50 PM
King Laura G.DirectorNov 03 '26Sale25.004,800120,00020,769Nov 05 05:01 PM
King Laura G.DirectorNov 03 '26Proposed Sale25.004,800120,000Nov 03 01:47 PM
William W Burkeboard of directorAug 19 '26Proposed Sale23.6015,000354,000Aug 20 02:05 PM
Dodd Sheri LouiseChief Executive OfficerAug 10 '26Sale29.4410,978323,243232,907Aug 12 04:22 PM
Dodd Sheri LouiseOfficerAug 10 '26Proposed Sale29.4410,978323,243Aug 10 05:53 PM
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERMay 11 '26Sale24.494,631113,404130,188May 13 05:01 PM
Birkemeyer Elaine M.OfficerMay 11 '26Proposed Sale24.494,631113,404May 11 03:21 PM
Dodd Sheri LouiseChief Executive OfficerFeb 24 '26Sale28.9410,993318,144243,885Feb 26 04:57 PM
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERFeb 24 '26Sale28.947,701222,880134,819Feb 26 04:56 PM
Burns KristieSr. VP Mktg & Clinical AffairsFeb 24 '26Sale28.946,246180,76482,581Feb 26 04:55 PM
Burns KristieOfficerFeb 25 '26Proposed Sale28.474,000113,880Feb 25 10:01 AM
Birkemeyer Elaine M.CHIEF FINANCIAL OFFICERFeb 23 '26Sale28.305,518156,144142,520Feb 24 05:33 PM
Dodd Sheri LouiseChief Executive OfficerFeb 23 '26Sale28.3015,240431,245254,878Feb 24 05:32 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
DFATU.S. Targeted Value Portfolio-ETF Class Shares-
DFSVUS Small Cap Value Portfolio ETF Class Shares-
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
BSVOEA Bridgeway Omni Small-Cap Value ETFAUM: 2.44B
FDLSInspire Fidelis Multi Factor ETFAUM: 251.04M

News

latest 14 of 200
  • Tactile Systems Technology: Q3 Earnings Snapshot (Associated Press) +8.35%
  • Tactile Medical Squeaks Past EPS Estimates As Accelerating Lymphedema Growth Offsets A Deepening AffloVest Inventory Hole (Earnings Whispers)
  • Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results (GlobeNewswire)
  • Tactile Medical Needs Lymphedema To Carry Q3 As AfloVest Inventory Drag Lingers (Earnings Whispers)
  • Tactile Medical to Release Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 (GlobeNewswire)
  • Anteris Technologies appoints Brent Moen as chief financial officer (Proactive)
  • Tactile Systems Technology: Q2 Earnings Snapshot (Associated Press) -17.12%
  • Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results (GlobeNewswire)
  • Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026 (GlobeNewswire)
  • Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve Wearable Compression Device for VA and DoD Patients (GlobeNewswire)
  • Tactile Medical Launches Next-Generation AffloVest Airway Clearance Therapy (GlobeNewswire)
  • Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference (GlobeNewswire)
  • Tactile Systems Technology: Q1 Earnings Snapshot (Associated Press) +7.22%
  • Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-020.3100.2770.31091.8691.993
2026Q22026-08-100.3400.1350.33885.7085.524
2026Q12026-05-04-0.080-0.120-0.07875.2770.574
2025Q42026-02-170.4600.4370.462103.5993.804
2025Q32025-11-030.3600.1680.36585.7679.304
2025Q22025-08-040.1400.1080.13878.9173.934
2025Q12025-05-05-0.130-0.080-0.12561.2763.484
2024Q42025-02-180.4000.3150.39785.5985.404
2024Q32024-11-040.2100.1830.21373.0976.024
2024Q22024-08-050.1990.1450.17873.2272.954
2024Q12024-05-06-0.050-0.078-0.09361.0959.184
2023Q42024-02-200.3800.2120.34577.6578.343
2023Q32023-11-060.8530.0280.93569.5969.084
2023Q22023-08-070.049-0.050-0.00468.3465.284
2023Q12023-05-08-0.033-0.239-0.08958.8553.944
2022Q42023-02-210.2920.1430.22873.9070.534

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY0.3100.1580.310109.28108.24
2018FY0.3400.3440.342143.75140.73
2019FY0.5600.5830.559184.47187.88
2020FY-0.030-0.246-0.032187.13186.11
2021FY-0.333-0.160-0.599208.06204.36
2022FY-0.180-0.240-0.890246.79243.4
2023FY1.2731.0811.230274.42275.13
2024FY0.7000.6150.703292.98292.8
2025FY0.8200.7960.820329.52319.74
2026FY-1.130--362.51
2027FY-1.497--396.73
2028FY-1.965--428.83

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-03401109.65109.22110.2
2026Q4S2026-11-02400109.43108.3111.5
2026Q4S2026-10-25400109.43108.3111.5
2026Q4S2026-10-09402109.43108.3111.5
2026Q4S2026-08-27402109.44108.3111.54
2026Q4S2026-08-19503108.41104.3111.54
2026Q4S2026-08-11503108.41104.3111.54
2026Q4S2026-07-19500110.49108.9113
2026Q4S2026-07-10502110.49108.9113
2026Q4S2026-05-19502110.49108.9112.95
2026Q4S2026-05-05502110.49108.9113
2026Q4S2026-05-04500112.03110.13114.4
2026Q4S2026-02-18550112.03110.13114.4
2026Q4S2026-01-1850010198.90102.5

Estimate history

EPS, annual0.310.3420.559-0.032-0.599-0.891.230.7030.8191.0316
Period201720182019202020212022202320242025TTM
EPS, quarterly0.2130.397-0.1250.1380.3650.462-0.0780.3380.311
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual109.283143.751189.492187.13208.057246.785274.423292.984329.522356.42
Period201720182019202020212022202320242025TTM
Sales, quarterly73.09385.58561.26878.90585.755103.59475.26785.69891.858
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual17.84618.63119.15319.49319.87820.25323.60123.88322.43922.496
Period201720182019202020212022202320242025MRQ
Shares, quarterly23.99723.88323.58422.29222.33622.43922.7122.70122.496
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue356.42329.52292.98274.42246.78208.06187.13189.49143.75
Cost of Goods Sold Incl. D&A84.4381.8278.8381.8474.5859.1154.3255.2641.49
Gross Profit271.98247.70214.16192.58172.21148.95132.81134.24102.26
Selling, General and Administrative Excl. Other238.26218.42191.98177.02174.30149.24132.84122.6499.27
Research and Development10.318.488.837.827.095.665.265.175.29
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income33.7229.2822.1815.57-2.09-0.29-0.0311.602.99
Interest Expense0.081.042.08---0.000.00-
Unusual Expense0.060.000.00-2.4810.660.002.401.10-
Net Income Before Taxes36.0531.3423.4915.77-15.47-2.29-2.2611.133.48
Income Taxes12.2412.256.53-12.742.399.52-1.640.16-3.15
Consolidated Net Income23.8219.0916.9628.52-17.87-11.81-0.6210.976.62
Net Income From Continuing Operations23.8219.0916.9628.52-17.87-11.81-0.6210.976.62
Net Income23.8219.0916.9628.52-17.87-11.81-0.6210.976.62
EPS (Recurring)1.040.820.701.16-0.52-0.600.050.600.34
EPS (Basic, Before Extraordinaries)1.060.830.711.24-0.89-0.60-0.030.580.36
EPS (Diluted)1.030.820.701.23-0.89-0.60-0.030.560.34
EBITDA40.5635.9228.9722.114.173.402.7715.146.62
Non-Operating Income (Expense)2.473.103.39-2.27-2.71-0.530.170.630.49
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.076.606.185.967.587.437.807.176.30
Price To Earnings Ratio25.8025.8026.6613.37---120.88135.08
Price To Sales Ratio1.442.051.411.210.931.804.657.006.13
Gross Margin76.3175.1773.1070.1869.7871.5970.9770.8471.14
Operating Margin9.468.897.575.67-0.85-0.14-0.016.122.08
Net Margin6.685.795.7910.39-7.24-5.68-0.335.794.61
Shares Outstanding22.5022.4423.8823.6020.2519.8819.4919.1518.63
Market Capitalization596.33596.33411.07336.02231.38377.23872.951,284.58841.45

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue91.8685.7075.27103.5985.7578.9161.2785.58
Cost of Goods Sold Incl. D&A22.0021.0018.2523.1821.3520.7316.5521.85
Gross Profit69.8664.7057.0280.4164.4158.1744.7163.74
Selling, General and Administrative Excl. Other60.2057.8758.5561.6353.4454.0949.2651.22
Research and Development2.512.502.782.532.192.021.742.04
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income9.656.83-1.5318.7710.964.08-4.5412.52
Interest Expense0.020.020.030.010.190.410.422.08
Unusual Expense0.060.000.000.000.000.000.000.00
Net Income Before Taxes10.137.37-0.9019.4511.444.52-4.0712.99
Income Taxes2.97-0.420.878.813.231.31-1.103.27
Consolidated Net Income7.167.79-1.7610.638.213.22-2.979.72
Net Income From Continuing Operations7.167.79-1.7610.638.213.22-2.979.72
Net Income7.167.79-1.7610.638.213.22-2.979.72
EPS (Recurring)0.310.34-0.080.460.360.14-0.130.40
EPS (Basic, Before Extraordinaries)0.320.34-0.080.470.370.14-0.130.40
EPS (Diluted)0.310.34-0.080.460.360.14-0.130.40
EBITDA11.438.640.1020.4012.605.74-2.8214.23
Non-Operating Income (Expense)0.560.560.670.690.670.850.902.56
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.881.791.412.011.431.531.631.46
Price To Earnings Ratio25.8033.6031.1437.4422.2315.3119.0426.66
Price To Sales Ratio1.441.961.722.031.000.791.071.43
Gross Margin76.0575.5075.7577.6275.1073.7372.9874.47
Operating Margin10.517.97-2.0418.1212.785.17-7.4114.62
Net Margin7.799.08-2.3410.279.574.08-4.8511.35
Shares Outstanding22.5022.7022.7122.4422.3422.2923.5823.88
Market Capitalization596.33671.73594.47647.73308.52235.74311.80411.07

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments83.4594.3761.0321.9328.2347.8545.2345.8843.91
Short Term Receivables59.6359.4857.3770.9661.9654.5641.5926.1219.74
Inventories14.0318.6722.5323.1219.2218.5619.0611.1911.04
Other Current Assets8.075.054.373.754.142.642.451.762.18
Total Current Assets165.17177.56145.29119.76113.55123.61108.3384.9676.87
Net Property, Plant & Equipment18.9122.2425.3227.4030.7327.0923.294.813.78
Total Investments and Advances0.000.300.300.300.300.300.000.000.00
Long-Term Note Receivable0.000.0010.9423.0612.859.434.181.882.72
Intangible Assets70.2373.8577.7981.4485.141.685.315.342.22
Deferred Tax Assets15.0123.7325.51-0.0010.208.978.822.66
Other Assets9.855.662.423.041.701.771.661.260.20
Total Assets279.17303.34287.57255.00244.27174.09151.75107.0788.45
Short Term Debt Incl. Current Port. of LT Debt3.195.945.765.475.472.011.450.010.02
Accounts Payable4.975.656.669.985.024.203.845.114.25
Income Tax Payable1.430.271.472.340.022.660.630.171.07
Other Current Liabilities31.3728.8527.1746.5423.9617.8515.5010.799.18
Total Current Liabilities40.9640.7041.0664.3334.4626.7121.4316.0814.52
Long Term Debt12.7639.1744.6166.7675.1419.3915.130.000.00
Provision for Risks Charges1.041.211.682.213.113.232.541.731.14
Deferred Tax Liabilities5.225.426.13-0.03----
Other Liabilities0.280.240.450.303.300.000.050.000.00
Total Liabilities60.2686.7593.92133.60116.0449.3439.1617.8015.66
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity218.90216.60193.64121.40128.23124.75112.5989.2772.79
Total Shareholders Equity218.90216.60193.64121.40128.23124.75112.5989.2772.79
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity218.90216.60193.64121.40128.23124.75112.5989.2772.79
Total Liabilities & Stockholders Equity279.17303.34287.57255.00244.27174.09151.75107.0788.45
Book Value Per Share9.769.078.205.996.456.405.884.794.08
Tangible Book Value Per Share6.635.984.911.972.176.315.604.503.95
Full-Time Employees1,0861,037992982988707629499406
Price to Book Ratio2.641.981.842.022.957.0211.489.517.47
Return on Assets6.555.7410.51-7.16-5.65-0.388.486.777.21
Return on Equity8.778.2718.10-14.31-9.34-0.5210.878.178.84
Return on Invested Capital8.246.6311.97-9.50-5.81-0.438.597.428.04
Quick Ratio3.693.902.991.502.743.934.174.594.53
Current Ratio4.034.363.541.863.294.635.065.285.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income23.8219.0916.9628.52-17.87-11.81-0.6210.976.62
Depreciation6.846.646.796.546.273.682.793.543.63
Other Funds (Non Cash)9.108.448.134.9521.439.9914.6110.6710.51
Funds from Operations46.7742.6932.9520.639.8012.0915.5525.0414.59
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-14.580.127.7115.10-4.63-9.46-12.76-22.52-5.57
Income Taxes Payable-1.711.19-1.40-0.722.27-2.291.972.430.17
Cash from Operating Activities32.1942.8140.6635.735.172.632.792.519.02
Capital Expenditures-3.33-2.54-2.51-2.48-1.92-2.35-2.29-5.99-9.55
Net Assets From Acquisitions-6.230.000.000.000.00-79.830.000.00-
Sale of Fixed Assets and Businesses0.000.000.010.000.010.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.0022.503.65-4.68
Purchase of Investments0.000.000.000.000.000.000.00-22.84-21.68
Sale Or Maturity of Investments0.000.000.000.000.000.0022.5026.4917.00
Other Uses-3.000.000.000.000.000.00-0.030.00-0.50
Other Sources0.000.000.000.000.00-0.00-0.00
Cash from Investing Activities-12.56-2.54-2.50-2.48-1.91-82.1820.18-2.33-14.73
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-10.49-24.95-1.8236.181.446.293.975.894.23
Repurchase of Common Pref Stock-12.53-26.56-3.510.000.000.000.000.000.00
Sale of Common Pref Stock2.041.611.6836.181.446.293.975.894.23
Proceedsfrom Stock Options2.421.391.6636.171.292.312.903.052.71
Issuance or Reduction of Debt, Net0.00-26.25-3.00-19.75-6.0054.810.000.00-0.01
Change in Long Term Debt0.00-26.25-3.00-19.75-6.0054.810.000.000.00
Issuance of Long Term Debt0.000.000.008.250.0054.810.000.000.00
Reduction of Long Term Debt0.00-26.25-3.00-28.00-6.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-10.57-5.00-1.17-1.85-3.39-2.38
Other Financing Activities Uses0.000.000.00-10.57-5.00-1.17-1.85-3.39-2.38
Cash from Financing Activities-10.49-51.20-4.825.86-9.5659.932.112.501.84
Net Change in Cash9.14-10.9233.3339.10-6.30-19.6325.092.67-3.87
Free Cash Flow29.0240.4338.2633.413.390.530.73-2.944.82
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow17.7016.7110.819.9267.96710.721,182.93-182.73
Deferred Taxes & Investment Tax Credit-8.531.07-19.38-0.0310.23-1.23-0.15-6.18

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments75.1169.8574.9983.4565.9781.53
Short Term Receivables63.7658.9853.4259.6352.1048.00
Inventories15.6016.8416.5814.0316.0817.11
Other Current Assets12.3111.937.858.077.256.35
Total Current Assets166.78157.60152.84165.17141.40152.99
Net Property, Plant & Equipment20.9718.4018.5118.9120.2120.36
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets83.2884.3081.8670.2371.0971.97
Deferred Tax Assets8.708.708.7215.0116.7518.33
Other Assets11.5810.6610.199.859.749.40
Total Assets291.29279.67272.12279.17259.18273.05
Short Term Debt Incl. Current Port. of LT Debt3.253.103.243.193.146.05
Accounts Payable11.797.927.124.977.998.03
Income Tax Payable0.000.002.161.431.200.00
Other Current Liabilities32.4627.2323.4931.3726.8526.33
Total Current Liabilities47.5038.2536.0140.9639.1940.40
Long Term Debt13.8211.2711.9412.7613.5936.12
Provision for Risks Charges1.091.081.071.041.121.24
Deferred Tax Liabilities---5.22--
Other Liabilities1.635.235.230.280.330.35
Total Liabilities64.0455.8354.2560.2654.2378.12
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity227.25223.84217.87218.90204.95194.93
Total Shareholders Equity227.25223.84217.87218.90204.95194.93
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity227.25223.84217.87218.90204.95194.93
Total Liabilities & Stockholders Equity291.29279.67272.12279.17259.18273.05
Book Value Per Share10.109.869.599.769.188.74
Tangible Book Value Per Share6.406.155.996.635.995.52
Full-Time Employees---1,086--
Price to Book Ratio2.643.102.683.161.581.16
Return on Assets8.659.007.356.556.645.48
Return on Equity11.0211.889.598.778.807.64
Return on Invested Capital2.973.31-0.774.593.761.39
Quick Ratio3.183.683.783.693.203.36
Current Ratio3.514.124.244.033.613.79

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income7.167.79-1.7610.638.213.22
Depreciation1.771.811.641.621.641.66
Other Funds (Non Cash)2.442.261.852.551.812.00
Funds from Operations11.3811.871.7521.7613.256.60
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.60-8.62-2.09-4.47-2.918.15
Income Taxes Payable0.37-3.070.830.171.640.74
Cash from Operating Activities11.983.25-0.3417.3010.3414.76
Capital Expenditures-0.60-1.32-0.83-0.58-1.15-0.40
Net Assets From Acquisitions0.000.00-6.230.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.00-3.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.60-4.32-7.06-0.58-1.15-0.40
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-6.12-4.08-1.050.760.00-15.70
Repurchase of Common Pref Stock-6.17-5.28-1.070.000.00-16.54
Sale of Common Pref Stock0.051.210.020.760.000.84
Proceedsfrom Stock Options0.001.030.001.390.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-24.75-0.75
Change in Long Term Debt0.000.000.000.00-24.75-0.75
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00-24.75-0.75
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-6.12-4.08-1.050.76-24.75-16.45
Net Change in Cash5.26-5.14-8.4517.48-15.56-2.09
Free Cash Flow11.431.97-1.1616.799.2214.39
Price to Free Cash Flow17.7025.6115.0316.537.885.95

Revenue breakdown

Airway clearance products2024: 33.62M 2025: 51.14M
Lymphedema products2024: 259.36M 2025: 278.38M
United States2024: 292.98M 2025: 329.52M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.88%2.8M21.7M284.20K
2026-10-1512.93%2.8M21.9M291.36K
2026-09-3013.14%2.8M21.7M295.32K
2026-09-1512.98%2.8M21.7M298.76K
2026-08-3112.04%2.6M21.7M288.05K
2026-08-1411.77%2.6M21.7M277.11K
2026-07-3110.82%2.4M21.7M289.41K
2026-07-1511.27%2.4M21.7M300.66K
2026-06-3011.24%2.4M21.7M301.41K
2026-06-1510.61%2.3M21.7M293.61K
2026-05-2910.87%2.4M21.7M304.04K
2026-05-1510.60%2.3M21.7M367.82K
2026-04-308.36%1.8M21.9M323.29K
2026-04-157.63%1.7M21.7M324.65K
2026-03-317.71%1.7M21.7M347.31K
2026-03-138.74%1.9M21.7M354.61K
2026-02-278.17%1.7M21.4M371.46K
2026-02-138.58%1.8M21.5M347.90K
2026-01-308.53%1.8M21.4M472.47K
2026-01-158.67%1.9M21.4M446.96K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.5012.3016.300.006.1300.000.000.897-0.2670.008
call15.009.8013.800.004.8930.000.000.870-0.2590.009
call17.507.3011.300.004.0400.000.000.836-0.2450.010
call20.004.808.804.023.2112.000.000.794-0.2250.012
call22.502.406.404.752.53210.000.000.737-0.2020.014
call25.000.804.303.652.05438.000.000.649-0.1740.016
call30.000.100.150.100.5954733,0780.126-0.0290.009
call35.000.002.150.001.1950.000.000.092-0.0460.007
call40.000.002.150.001.5220.000.000.060-0.0420.005
put12.500.002.150.006.3270.000.00-0.103-0.2650.008
put15.000.002.150.005.1760.000.00-0.131-0.2570.009
put17.500.002.150.004.2020.000.00-0.164-0.2430.010
put20.000.002.150.053.34612.000.00-0.205-0.2220.012
put22.500.002.200.302.6195.000.00-0.263-0.1990.014
put25.000.002.351.511.98010.000.00-0.350-0.1720.016
put30.001.355.100.001.8360.000.00-0.875-0.0260.009
put35.006.209.800.002.3950.000.00-0.924-0.0340.006
put40.0011.2015.200.003.2660.000.00-0.940-0.0380.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-064Statement of changes in beneficial ownership of securities2026-11-04SEC
2026-11-063Initial statement of beneficial ownership of securities2026-11-02SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0310-Q/A2026-06-30SEC
2026-11-0310-Q/A2025-09-30SEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-06-01SDSpecialized Disclosure ReportSEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-11SEC
2026-05-11144Filing for proposed sale of securities under Rule 144.SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-05-06SEC
2026-05-078-KCurrent report2026-05-06SEC
2026-05-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100255.00K2
2026-100000
2026-090000
2026-0800323.24K1
2026-070000
2026-060000
2026-0500113.40K1
2026-040000
2026-030000
2026-02001.43M6
2026-0100148.26K1
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.8.45%
CADIAN CAPITAL MANAGEMENT, LP6.99%
DIMENSIONAL FUND ADVISORS LP4.99%
MORGAN STANLEY4.34%
VANGUARD CAPITAL MANAGEMENT LLC4.30%
DRIEHAUS CAPITAL MANAGEMENT LLC4.16%
ACADIAN ASSET MANAGEMENT LLC3.32%
VANGUARD PORTFOLIO MANAGEMENT LLC3.13%
FEDERATED HERMES, INC.3.02%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP2.83%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.04%
iShares Russell 2000 ETF2.65%
Janus Henderson Small Cap Value Fund1.76%
Federated Hermes MDT Small Cap Core Fund1.46%
VANGUARD EXTENDED MARKET INDEX FUND1.16%
Fidelity Small Cap Index Fund1.11%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.84%
iShares Russell 2000 Growth ETF0.80%
U.S. Targeted Value Portfolio0.73%
U.S. SMALL CAP VALUE PORTFOLIO0.70%

OakChart. TCMD. Cached 15 minutes.